# Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic Syndrome

> **NCT00488436** · PHASE4 · COMPLETED · sponsor: **PETHEMA Foundation** · enrollment: 25 (estimated)

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Antithymocyte globulin
- **DRUG:** Cyclosporine

## Key facts

- **NCT ID:** NCT00488436
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** 2007-06
- **Final completion:** 2007-12
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2008-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00488436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00488436, "Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00488436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*